Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Israel"

64 News Found

Biohaven and Pfizer announce positive topline results of rimegepant to treat migrane
Biotech | February 14, 2022

Biohaven and Pfizer announce positive topline results of rimegepant to treat migrane

Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific


Glenmark launches nasal spray to treat Covid-19
News | February 09, 2022

Glenmark launches nasal spray to treat Covid-19

Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process


Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval
Biotech | February 01, 2022

Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval

Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel


Pharma industry seeks fiscal support to drive innovation
News | January 31, 2022

Pharma industry seeks fiscal support to drive innovation

Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India


U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
News | January 03, 2022

U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older

First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age


Novel Concepts Medical’s formula disrupts Covid-19 spike protein
Biotech | December 17, 2021

Novel Concepts Medical’s formula disrupts Covid-19 spike protein

The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours


U.S. FDA approves Bristol Myers Squibb’s Orencia
Drug Approval | December 16, 2021

U.S. FDA approves Bristol Myers Squibb’s Orencia

Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant


J&J booster after the two-dose Pfizer-BioNTech vaccine increases antibody and T-cell responses
News | December 06, 2021

J&J booster after the two-dose Pfizer-BioNTech vaccine increases antibody and T-cell responses

These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv


Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
News | October 25, 2021

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.